Horizon Discovery
2033 Westport Center Dr
St. Louis
Missouri
63146
United States
Tel: (314) 400-6627
Website: http://www.horizondiscovery.com/
Email: info@horizondiscovery.com
124 articles about Horizon Discovery
-
PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million)
11/2/2020
Addition of CRISPR and RNAi offerings to complement PerkinElmer's life sciences and applied genomics solutions, with future opportunities to improve cell based discovery for precision medicine
-
Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service
8/4/2020
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced the addition of single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio.
-
Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics
7/29/2020
Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that TrueBinding, Inc. (“TrueBindi
-
Horizon Discovery Introduces Cas9 and dCas9-VPR Stable Cell Lines to Simplify and Accelerate CRISPR Gene Editing Workflows
7/7/2020
QC-validated cell lines optimized to work alongside Horizon’s Edit-R predesigned sgRNA products and DharmaFECT transfection reagents
-
Rentschler Biopharma Licenses Horizon Discovery’s CHOSOURCE Platform to Complement Cell Line Development Offering for Difficult-To-Express Proteins
5/19/2020
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield
-
BioSpace Global Roundup, April 16
4/16/2020
Global pharma and life sciences companies provide updates on their business operations and pipelines. -
BioSpace Global Roundup, Jan. 16
1/16/2020
Companies from across the globe provide updates to their business and pipeline. -
Exercises Option to Exclusively License Base Editing Technology from Rutgers, The State University of New Jersey
1/14/2020
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has exercised its option to exclusively license a novel Base Editing technology from Rutgers, The State University of New Jersey, for use in therapeutic, diagnostic and service applications.
-
Horizon Discovery to Provide Access to Novel Base Editing Technology
1/14/2020
Horizon Discovery Group plc announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications.
-
Horizon Discovery Group plc: Strategic collaboration in bioproduction with Mammoth Biosciences
12/13/2019
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces a strategic collaboration with Mammoth Biosciences, that will see the two companies develop new CRISPR tools to provide the next generation of engineered cell lines for the biopharmaceutical industry.
-
BioSpace Global Roundup, Dec. 12
12/12/2019
Companies from across the globe provide updates to their business and pipelines. -
Horizon Discovery introduces predesigned synthetic sgRNAs to streamline CRISPR gene editing workflows
12/9/2019
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announced the addition of predesigned synthetic single guide RNA to its product range.
-
BioSpace Global Roundup, Dec. 5
12/5/2019
Companies from across the globe provide updates on their business and pipelines. -
Horizon Discovery Partners With the Human Protein Atlas
12/3/2019
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced that it has entered into a partnership with The Human Protein Atlas.
-
Horizon Discovery Divests Animal Models Business to Envigo
11/8/2019
Horizon Discovery Group plc announces an agreement to divest the Group’s animal research models business unit to Envigo RMS LLC (“Envigo”).
-
BioSpace Global Roundup, Oct. 3
10/3/2019
Companies from across the globe share information on their business and pipelines. -
Horizon Discovery Signs License Agreement With Glenmark Pharmaceuticals for GS Knockout CHO Cell Line for Manufacture of Biotherapeutics
9/30/2019
Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells
-
Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019
9/16/2019
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.
-
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics
9/3/2019
Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines.
-
Horizon Discovery Group plc: Trading Update
7/24/2019
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, provides a trading update for the six month period ended 30 June 2019.